Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal ...
Earendil Labs, WuXi Earendil Biologics collaborate to speed up development and manufacturing of bispecific/multispecific antibodies & ADCs: Wilmington, Delaware Monday, March 16, ...
From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. | From its ...
WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual ...
Codexis, Inc. (NASDAQ:CDXS) Q4 2025 Earnings Call Transcript March 11, 2026 Codexis, Inc. beats earnings expectations. Reported EPS is $0.1056, expectations were $-0.03. Operator: Greetings. Welcome ...
PDA Publishes Revised Technical Report No. 56: A Clear, Phase Appropriate Roadmap for GMP Compliant Development of Biological Drug Substances Technical Report No. 56 (Revised 2026) outlines a ...
Controlling drug-to-antibody ratio and scalable reactors are key to reliable antibody-drug conjugate manufacturing success.
Patrys kicks off RLS-2201 manufacturing with BioCina and FDA 505(b)(2) engagement, targeting Phase 0 trials in H2 2026.
Nina Bauer of FUJIFILM Cellular Dynamics shares insight on addressing challenges and supporting developers heading towards commercialization.
ViruSure, an Asahi Kasei company and global leader in pathogen safety testing for biopharmaceuticals, today announced the launch of the world's first GMP-validated adventitious viral agent (AVA) ...
Integrating Asymchem’s Payload–Linker Facility to Provide End-to-End, One-Stop Services for Drug Conjugates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results